MiMedx
- Market cap
- 664.00M
- P/E (TTM)i
- 113.75
- P/Bi
- 3.07
- EPSi
- 0.32
- Div yieldi
- 0.00%
- 52W posi
- 31%
Anonymous reader poll. Unscientific, not investment advice.
About MiMedx
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
- Founded
- 1985
- CEO
- Mr. Joseph H. Capper
- Employees
- 808
- Headquarters
- Marietta, Georgia, United States of America
- Fiscal year end
- 12-31
- Website
- mimedx.com
Company profile
- Exchange
- US
- Symbol
- MDXG
- Market-cap rank
- #3541
- Market cap
- 664.00M
- Float cap
- 523.01M
- Shares out
- 145.93M
- Float shares
- 114.95M
Sectors & themes
Quote time 2026-10-08 09:59:07 · For reference only, not investment advice and not tailored to your situation.